Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

by Heidie Frisco Cabanos, Aaron N. Hata
Published 2021-05-01

Alginate-based 3D cancer cell culture for therapeutic response modeling

by Farideh Davoudi, Samar Ghorbanpoor, Satoshi Yoda, Xiao Pan, Giovanna Stein Crowther, Xunqin Yin, Ellen Murchie, Aaron N. Hata, Henning Willers, Cyril H. Benes
Published 2021-06-01

Targeting the DNA replication stress phenotype of KRAS mutant cancer cells

by Tara Al Zubaidi, O. H. Fiete Gehrisch, Marie-Michelle Genois, Qi Liu, Shan Lu, Jong Kung, Yunhe Xie, Jan Schuemann, Hsiao-Ming Lu, Aaron N. Hata, Lee Zou, Kerstin Borgmann, Henning Willers
Published 2021-02-01

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

by Lynnette Marcar, Kankana Bardhan, Liliana Gheorghiu, Patrick Dinkelborg, Heike Pfäffle, Qi Liu, Meng Wang, Zofia Piotrowska, Lecia V. Sequist, Kerstin Borgmann, Jeffrey E. Settleman, Jeffrey A. Engelman, Aaron N. Hata, Henning Willers
Published 2019-06-01

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

by Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima, Yuki Shimizu, Yosuke Seto, Tomoko Oh-hara, Sumie Koike, Naoki Nakao, Hiroyuki Hanzawa, Kengo Watanabe, Satoshi Yoda, Noriko Yanagitani, Aaron N. Hata, Alice T. Shaw, Makoto Nishio, Naoya Fujita, Takeshi Isoyama
Published 2019-08-01